Trial · NCT00957905
Adverse events82
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 82
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alkaline phosphatase increased | Investigations | Part A (Alvocidib and Oxaliplatin) | 2 | 7 | 5 |
| other | Alkaline phosphatase increased | Investigations | Part B (Alvocidib and FOLFOX) | 2 | 29 | 7 |
| other | Anemia | Blood and lymphatic system disorders | Part A (Alvocidib and Oxaliplatin) | 2 | 7 | 18 |
| other | Anemia | Blood and lymphatic system disorders | Part B (Alvocidib and FOLFOX) | 8 | 29 | 46 |
| other | Blood bilirubin increased | Investigations | Part A (Alvocidib and Oxaliplatin) | 1 | 7 | 3 |
| other | Blood bilirubin increased | Investigations | Part B (Alvocidib and FOLFOX) | 0 | 29 | 0 |
| other | Creatinine increased | Investigations | Part A (Alvocidib and Oxaliplatin) | 1 | 7 | 3 |
| other | Creatinine increased | Investigations | Part B (Alvocidib and FOLFOX) | 1 | 29 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Part A (Alvocidib and Oxaliplatin) | 1 | 7 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Part B (Alvocidib and FOLFOX) | 4 | 29 | 10 |
| other | Hyperglycemia | Metabolism and nutrition disorders | Part A (Alvocidib and Oxaliplatin) | 1 | 7 | 1 |
| other | Hyperglycemia | Metabolism and nutrition disorders | Part B (Alvocidib and FOLFOX) | 5 | 29 | 10 |
| other | Hypermagnesemia | Metabolism and nutrition disorders | Part A (Alvocidib and Oxaliplatin) | 1 | 7 | 1 |
| other | Hypermagnesemia | Metabolism and nutrition disorders | Part B (Alvocidib and FOLFOX) | 0 | 29 | 0 |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Part A (Alvocidib and Oxaliplatin) | 1 | 7 | 1 |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Part B (Alvocidib and FOLFOX) | 4 | 29 | 9 |
| other | Hypocalcemia | Metabolism and nutrition disorders | Part A (Alvocidib and Oxaliplatin) | 1 | 7 | 12 |
| other | Hypocalcemia | Metabolism and nutrition disorders | Part B (Alvocidib and FOLFOX) | 6 | 29 | 16 |
| other | Hypokalemia | Metabolism and nutrition disorders | Part A (Alvocidib and Oxaliplatin) | 1 | 7 | 2 |
| other | Hypokalemia | Metabolism and nutrition disorders | Part B (Alvocidib and FOLFOX) | 1 | 29 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00957905/events